Jokowi's First Vaccine, Kimia Farma's Stock Price Is The Champion Of Kaesang, Instead Of Amblas

JAKARTA - President Joko Widodo (Jokowi) is the first person to receive the COVID-19 vaccine in the national vaccination program which starts today, Wednesday, January 13. However, this is like an anomaly because pharmaceutical company shares have collapsed on the stock exchange, as experienced by PT Kimia Farma Tbk.

At the close of trading today, the stock price of the issuer coded KAEF fell 6.81 percent to a level of Rp6,500. At the close of trading yesterday, Kimia Farma's shares were at the level of Rp6,975 per share.

In fact, the Composite Stock Price Index (IHSG) was at its peak, having strengthened again for five days in a row. Today, JCI rose 0.62 percent or 39.54 points to 6,435.20.

KAEF is one of the favorite stocks of Jokowi's son, Kaesang Pangarep. The youngest son of the Indonesian head of state often recommends KAEF shares, especially when the Sinovac vaccine landed for the first time in Indonesia in early December 2020.

Not only Kimia Farma, shares of other pharmaceutical issuers also fell significantly. Shares of PT Indofarma Tbk (INAF) for example, fell 6.81 percent to the level of Rp6,500

Then the shares of another pharmaceutical issuer, PT Kalbe Farma Tbk (KLBF) fell 6.85 percent to Rp1,565. PT Phapros Tbk (PEHA) is also worth three coins, which weakened 6.82 percent to IDR2,460 per share.